Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

Oncologist

Volumn 15, Issue 3, 2010, Pages 246-252

  Lehmann Che, Jacqueline ^a   André, Fabrice ^b   Desmedt, Christine ^c   Mazouni, Chafika ^d   Giacchetti, Sylvie ^e   Turpin, Elisabeth ^a   Espié, Marc ^e   Plassa, Louis François ^a   Marty, Michel ^e   Bertheau, Philippe ^f   Sotiriou, Christos ^c   Piccart, Martine ^c   Symmans, W Fraser ^g   Pusztai, Lajos ^g   de Thé, Hugues ^a  

^a Institut Universitaire d'Hématologie   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d Laboratoire de Transfert Biologique Oncologique   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROTEIN P53; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 77950530561     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0243     Document Type: Article

References (38)

1. Andre F, Pusztai L. Molecular classification of breast cancer: Implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006;3:621-632.
2. Pritchard KI, Messersmith H, Elavathil L et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-744.
3. Rouzier R, Rajan R, Wagner P et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-8320.
4. Vogelstein B, Kinzler KW. Achilles' heel of cancer? Nature 2001;412: 865-866.
5. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-240.
6. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-898.
7. Bunz F, Hwang PM, Torrance C et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269.
8. Berns A. Cancer biology: Can less be more for p53? Nature 2006;443:153-154.
9. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 1999;80:1968-1973.
10. Manié E, Vincent-Salomon A, Lehmann-Che J et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009;69:663-671.
11. Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007;104:12111-12116.
12. Petitjean A, Achatz MI, Borresen-Dale AL et al. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-2165.
13. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207.
14. Irwin MS. Family feud in chemosensitivity: p73 and mutant p53. Cell Cycle 2004;3:319-323.
15. Zheng H, Ying H, Yan H et al. p53 and Pten control neural and glioma stem/ progenitor cell renewal and differentiation. Nature 2008;455:1129-1133.
16. Aas T, Børresen AL, Geisler S et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
17. Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-2512.
18. Di Leo A, Tanner M, Desmedt C et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 2007;18:997-1003.
19. Bertheau P, Plassa F, Espié M et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002;360: 852-854.
20. Bertheau P, Turpin E, Rickman DS et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007;4:e90.
21. Bidard FC, Matthieu MC, Chollet P et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 2008;19:1261-1265.
22. Bonnefoi H, Diebold-Berger S, Therasse P et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: Are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003;14:406-413.
23. Cottu PH, Zelek L, Extra JM et al. High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients. Ann Oncol 1999;10:795-801.
24. Flaman JM, Frebourg T, Moreau V et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 1995;92: 3963-3967.
25. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
26. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008.
27. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671.
28. Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999;17:3374-3388.
29. Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858-1869.
30. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26.
31. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7-16.
32. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-553.
33. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.
34. Rahko E, Blanco G, Soini Y et al. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 2003;39:447-453.
35. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000;408:429-432.
36. Carey LA, Rugo HS, Marcom PK et al. EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer. J Clin Oncol 2008;26(15 suppl):1009.
37. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
38. Bertheau P, Lerebours F, Mounier N et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep 2005;14:513-520.